Verona Pharma Plc ADR (NASDAQ:VRNA) has a beta value of 0.19 and has seen 1.43 million shares traded in the last trading session. The company, currently valued at $5.75B, closed the last trade at $67.53 per share which meant it gained $4.21 on the day or 6.65% during that session. The VRNA stock price is -9.85% off its 52-week high price of $74.18 and 83.13% above the 52-week low of $11.39.
The consensus among analysts is that Verona Pharma Plc ADR (VRNA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
Sporting 6.65% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the VRNA stock price touched $67.53 or saw a rise of 6.36%. Year-to-date, Verona Pharma Plc ADR shares have moved 45.41%, while the 5-day performance has seen it change -6.53%. Over the past 30 days, the shares of Verona Pharma Plc ADR (NASDAQ:VRNA) have changed 25.22%.
Wall Street analysts have a consensus price target for the stock at $77.5, which means that the shares’ value could jump 12.86% from current levels. The projected low price target is $74.0 while the price target rests at a high of $83.0. In that case, then, we find that the current price level is -22.91% off the targeted high while a plunge would see the stock gain -9.58% from current levels.
Verona Pharma Plc ADR (VRNA) estimates and forecasts
The company’s shares have gained 79.65% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 7.21% over the past 5 years.
VRNA Dividends
Verona Pharma Plc ADR is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders
The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 7.63 million shares worth more than $110.37 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 1.1775% of shares outstanding.
The other major institutional holder is NEA MANAGEMENT COMPANY, LLC, with the holding of over 5.58 million shares as of 2024-06-30. The firm’s total holdings are worth over $80.76 million and represent 0.8616% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MUTUAL FUND SERIES TRUST-Eventide Gilead Fund and MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund . As of Dec 31, 2024 , the former fund manager holds about 2.22% shares in the company for having 1.89 shares of worth $127.61 million while later fund manager owns 1.23 shares of worth $83.06 million as of Dec 31, 2024 , which makes it owner of about 1.45% of company’s outstanding stock.
